echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > EMA approves Ozawade to treat excessive daytime sleepiness (EDS)

    EMA approves Ozawade to treat excessive daytime sleepiness (EDS)

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Excessive daytime sleepiness (EDS) is a condition that can cause people to feel very sleepy during the day
    .


    Patients may sleep longer at night, nap during the day, or fall asleep at unusual or inappropriate times


    Usually, doctors can also prescribe neurostimulant drugs, such as modafinil (Provigil®) or methylphenidate (Ritalin®), to increase concentration and alertness
    .


    Patients should take the medicine as prescribed and consult a doctor or pharmacist before making any changes to the dosage or timing of the medicine


    Recently, the European Medicines Management Agency (EMA) has approved Bioprojet of Ozawade (pitolisant) for the treatment of obstructive sleep apnea (OSA) related to excessive daytime sleepiness (EDS)
    .

    manage

    Ozawade was evaluated in two phase III clinical studies (HAROSA I and HAROSA II) for the treatment of EDS in patients with OSA
    .


    These two studies showed that the Epwoth Sleepiness Scale (ESS) score of patients treated with Ozawade had a "significant improvement", and no significant improvement was observed.


    Two studies showed that the Epwoth Sleepiness Scale (ESS) score of patients treated with Ozawade had a “significant improvement”, and no significant improvement was observed.


    Jean-Charles Schwartz, Scientific Director and Co-founder of Bioprojet, said: “Due to fatigue, excessive daytime sleepiness is the most frequently reported symptom of patients, which has a considerable impact on the quality of life and daily safety.

    Ozawade provides an effective solution for all patients.


    Regardless of whether they are receiving PPC treatment or are intolerant to this treatment"


     

    Original source:

    Original source:

    http:// href="http://" target="_blank" rel="noopener">http:// http:// Leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.